| Ulcerative Colitis
Cyltezo vs Velsipity
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Cyltezo vs Velsipity with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVelsipity has a higher rate of injection site reactions vs Cyltezo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Velsipity but not Cyltezo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cyltezo
Velsipity
At A Glance
SC injection
Every other week
TNF-alpha inhibitor
Oral
Daily
S1P receptor modulator
Indications
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Panuveitis
- Ulcerative Colitis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg every other week SC; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Crohn Disease, Ulcerative Colitis 160 mg on Day 1, 80 mg on Day 15, then 40 mg every other week SC starting Day 29.
Psoriasis vulgaris, Panuveitis 80 mg initial dose, then 40 mg every other week SC starting 1 week after initial dose.
Ulcerative Colitis 2 mg orally once daily; swallow tablet whole, with or without food.
Contraindications
—
- Myocardial infarction, unstable angina pectoris, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- History or presence of Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, accidental injury, nausea, urinary tract infection, flu syndrome, abdominal pain, hyperlipidemia, back pain, hypertension, hematuria
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), malignancies, acute liver failure, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis
Most common (>=2%) Headache, elevated liver tests, dizziness, arthralgia, hypertension, urinary tract infection, nausea, hypercholesterolemia, herpes viral infection, bradycardia
Serious Infections, bradyarrhythmia and atrioventricular conduction delays, liver injury, macular edema, increased blood pressure, fetal risk, cutaneous malignancies, posterior reversible encephalopathy syndrome, respiratory effects
Pharmacology
Adalimumab-adbm is a TNF-alpha antagonist that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, modulating inflammatory responses and reducing concentrations of acute phase reactants such as CRP and ESR.
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 4, and 5, partially and reversibly blocking lymphocyte egress from lymphoid organs, thereby reducing peripheral blood lymphocyte counts and potentially limiting lymphocyte migration into the intestines.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cyltezo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Velsipity
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Cyltezo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Velsipity
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Cyltezo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Velsipity
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cyltezo.
Cost estimate not availableAssistance Fund: Ulcerative Colitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CyltezoView full Cyltezo profile
VelsipityView full Velsipity profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.